Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00968799
Recruitment Status : Terminated (poor patient accrual)
First Posted : August 31, 2009
Results First Posted : May 10, 2013
Last Update Posted : May 15, 2013
Information provided by (Responsible Party):
Sascha Müller, Cantonal Hospital of St. Gallen

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Epithelial Ovarian Cancer
Fallopian Tube Carcinoma
Interventions: Procedure: Hyperthermic intraoperative intraperitoneal chemotherapy
Procedure: Cytoreduction
Drug: Cisplatin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
overall recruitment was poor. study was terminated after 6 patients (of 27 scheduled)

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)

Tumor nodules are removed surgically. If necessary infested organs like colon are resected (=cytoreduction).

To destroy remaining tumor cells or invisible nodules the peritoneum is prefused with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).

If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).

Perfusion is performed with the open or Coliseum technique for 90 min.

Participant Flow:   Overall Study
Advanced disease, HIPEC not applicable                2 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
HIPEC Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC)

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   6 
>=65 years   0 
[Units: Years]
Mean (Standard Deviation)
 55  (6.6) 
[Units: Participants]
Female   6 
Male   0 
Region of Enrollment 
[Units: Participants]
Switzerland   6 

  Outcome Measures

1.  Primary:   Fitness for Systemic Chemotherapy   [ Time Frame: 3 months post operation ]

2.  Secondary:   Nephrotoxicity   [ Time Frame: 6 weeks post operation ]

3.  Secondary:   Surgical Complications   [ Time Frame: 6 weeks post operation ]

4.  Secondary:   Overall Survival   [ Time Frame: 5 years ]

5.  Secondary:   Pharmacokinetics   [ Time Frame: intraoperative and 1 week after surgery ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Sascha Müller, MD
Organization: Cantonal Hospital St.Gallen
phone: +41 71 494 1317

Responsible Party: Sascha Müller, Cantonal Hospital of St. Gallen Identifier: NCT00968799     History of Changes
Other Study ID Numbers: SGOV01
First Submitted: February 12, 2008
First Posted: August 31, 2009
Results First Submitted: March 26, 2013
Results First Posted: May 10, 2013
Last Update Posted: May 15, 2013